⌕

Revolution Medicines (RVMD) vs Zoetis (ZTS)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
59
Zoetis Inc
$83.82 · $34B · as of last close
CheapestBest incomeHighest quality
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is valuation.

#2 FIT
50
Revolution Medicines Inc
$172.29 · $37B · as of last close
Best returnsStrongest balance sheet
of the stocks compared here

The challenger. Trails the leader on the balanced score. Its widest win over the field is total return.

ZTS edges ahead (59/100 vs RVMD 50) under a balanced style, mostly on valuation. But RVMD wins on total return, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorRVMDZTS
Overall fit score
weighted for your balanced goal
50
6 of 8 factors known
✓ 59
Valuation
Cheaper for what you get
1×
P/E —
12
✓ P/E 14 · EV/EBITDA 10.7
P/E trailing
70
Growth
Revenue & earnings momentum
1×
—
—
✓ —
59
Profitability & quality
Margins & return on capital
1×
Net — · ROIC −58%
TTM through Sep 30, 2026
34
✓ Net 26% · ROIC 22%
TTM through Sep 30, 2026
69
Total return
Share-price change with dividends reinvested
1×
✓ 5Y +39%/yr
95
5Y −16%/yr
13
Risk (calm = better)
Volatility & drawdown
1×
β 1.1 · DD −57%
47
✓ β 0.6 · DD −70%
73
Balance sheet†
Debt vs cash cushion
1×
✓ Current ratio 8.36
Sep 30, 2026 balance sheet
73
Net debt/EBITDA 1.9×
TTM through Sep 30, 2026
38
Dividend & income
Cash paid to you
1×
—
40
✓ 2.53% yield· A+
96
Analyst sentiment
Forward EPS growth (consensus)
1×
no forward consensus
—
✓ Est EPS +0%/yr · 9 analysts
50
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
The letter beside the dividend yield is our dividend-safety grade (A+ to F), a read on how likely that dividend is to be cut. It does not grade the yield.
Loading chart…
WHERE EACH ONE IS STRONG
ValueQualityReturnSafetyIncome
Growth axis omitted: no data for one of these stocks.
■ RVMD■ ZTS
CAN YOU STOMACH THE RIDE?
Worst drawdown3-year beta vs S&P 500VolatilityHistory
RVMD−57%1.1562%5Y
ZTS−70%0.6230%5Y
Drawdown and volatility are measured over five years on the same total return as the chart, dividends reinvested.
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Leads on total return: 5Y +39%/yr (score 95).

▲ Leads on balance sheet (score 73). Current ratio 8.36 is one of the 5 inputs.

BEAR CASE

▼ Weakest on valuation: P/E — (score 12).

▼ Weakest on dividend & income: — (score 40).

BULL CASE

▲ Leads on valuation: P/E 14 · EV/EBITDA 10.7 (score 70).

▲ Leads on dividend & income: 2.53% yield (score 96).

BEAR CASE

▼ Weakest on total return: 5Y −16%/yr (score 13).

▼ Weakest on balance sheet (score 38). Net debt/EBITDA 1.9× is one of the 5 inputs.

WHAT COULD CHANGE THE SCORE
ValuationCurrently 12/100 (P/E —). Taking it to 100 would lift the balanced score by 15 points, the biggest single move available.
Profitability & qualityCurrently 34/100 (Net — · ROIC −58%). Taking it to 100 would lift the balanced score by 11 points, the next biggest.
Total returnCurrently 13/100 (5Y −16%/yr). Taking it to 100 would lift the balanced score by 10 points, the biggest single move available.
Balance sheetCurrently 38/100 (Net debt/EBITDA 1.9×). Taking it to 100 would lift the balanced score by 7 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 13, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.